Abstract: Objective: To compare the effects of Xuezhikang and Simvastain in patients with primary hyperlipidemia. Methods: One hundred eight patients with primary hyperlipidemia were randomly divided into two groups. Group 1, 53 patients, took 4 Xuezhikang capsules per day (1.2 g/d) for 8 weeks and Group 2, 55 patients took Simvastain 10 mg per day for 8 weeks. At the end of 8 weeks, the lipid levels were compared with those of the baseline in each group. Results: In Group 1, the serum levels of total cholesterol (TC), low-density lipoprotein (LDL) cholesterol and triglycerides (TG) decreased by 23.0%, 28.0% and 28.1% (P<0.001), and in Group 2 reduced by 23.3%, 29.5% and 29.5% (P<0.001) respectively. The serum levels of high-density lipoprotein (HDL) cholesterol after taking Xuezhikang increased by 5.0% (P>0.05) and after taking Simvastatin increased by 14.3% (P<0.01). No significant differences, however, were found between the two groups in TC, LDL cholesterol, TG and HDL cholesterol. The side effects of Xuezhikang were less than those of Simvastatin. Conclusion: Xuezhikang made in China is a safe, effective and well toleraled lipid modulator.

Key words: Hyperlipidemia, Hyperlipidemia, Xuezhikang, Xuezhikang, Simvastain, Simvastain